Immunovia AB (publ) (STO:IMMNOV)

Market Cap	70.72M
Revenue (ttm)	931.00K
Net Income (ttm)	-76.54M
Shares Out	261.91M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	976,824
Average Volume	2,329,406
Open	0.2840
Previous Close	0.2700
Day's Range	0.2615 - 0.2840
52-Week Range	0.2440 - 3.1500
Beta	2.76
RSI	39.55
Earnings Date	May 14, 2025

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 9
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IMMNOV

Financial Performance

In 2024, Immunovia AB's revenue was 931,000, a decrease of -40.89% compared to the previous year's 1.58 million. Losses were -76.54 million, -75.26% less than in 2023.